BRD2 and congenital hypogonadotropic hypogonadism: In hypogonadal men desiring fertility, hCG therapy–often supplemented with follicle-stimulating hormone (FSH) or human menopausal gonadotropin (hMG) to drive spermatogenesis–has proven successful, with the majority of cases achieving normal testosterone levels and restoring spermatogenesis (response rates ~85% in congenital hypogonadotropic hypogonadism) [100].